A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer

Inclusion Criteria: * Male or female ≥ 18 years of age * ECOG PS 0-2 * Histologically confirmed diagnosis of non-muscle invasive bladder cancer, naïve and recurrent. * Patients candidate to BCG or MMC intravesical induction therapy. * Transurethral resection (TURB/re-TURB when indicated) performed in the last 12 weeks. * IPSS score ≤19 * Negative urine culture within 2 weeks before T0 * For women who are not postmenopausal (i.e., \< 1 year after last menstruation) or surgical-ly sterile (absence of ovaries and/or uterus) and who are sexually active: agreement to use an adequate method of contraception (oral contraceptives, intrauterine contraceptive de-vice, or barrier method of contraception in conjunction with spermicidal jelly) during the study period * Signed the study informed consent prior to any study specific procedures. * Will and ability to comply with the protocol Exclusion Criteria: * Upper urinary tract urothelial carcinoma (UTUC); bladder diverticula; urethral stenosis; difficult catheterization; reduced bladder compliance; increased bladder compliance; post-voiding residue \> 150 ml; * Surgery or invasive procedures planned during the study and interfering with evaluation about efficacy and safety of it. * Female patients with child-bearing potential must not be pregnant or lactating, or not willing to use adequate contraception for the duration of study * Pelvic radiotherapy within 24 weeks prior to the beginning of the study treatment. * Urinary tract infection requiring antibiotics * Have a known hypersensitivity to any substance present in the investigational device. * Neurogenic bladder * Any condition for that, in the opinion of the Investigator, participation would not be in the best interest of the subject.